CD274 and renal cell carcinoma: Immune checkpoint blockade with antibodies that target programmed death 1 (PD1) or PD1 ligand 1 (PDL1) has revolutionized the treatment of advanced melanoma, non–small cell lung cancer, and renal cell carcinoma (RCC) (7–9).